publication venue for
- HIT: Lessons Learned 2006
- Thromboprophylaxis in Medical Patients – Why Not For All? 2006
- Direct Thrombin Inhibitors 1999
- For How Long Should the Treatment with Vitamin K Antagonists Be Maintained? 1999
- New antithrombotic drugs: Beyond aspirin and heparin - Chairman's summary 1999
- Optimization of treatment for venous thromboembolism and prevention of recurrences - Co-chairman's summary 1999
- Long-Term Prophylaxis in Venous Thromboembolism: LMWH or Oral Anticoagulation? 1998
- Comparison Of The Relative Efficacy And Safety Of Low Molecular Weight Heparin And Unfractionated Heparin For The Treatment Of Venous Thrombosis 1996
- INTRAVENOUS UROKINASE (UK) AND STREPTOKINASE (SK) IN ACUTE MYOCARDIAL-INFARCTION (AMI) - EVALUATION BY CK EVOLUTION AND ANGIOGRAPHY 1984
- SYSTEMIC LYTIC EFFECTS AND COAGULATION CHANGES WITH INTRAVENOUS THROMBOLYTIC THERAPY IN EVOLVING MYOCARDIAL-INFARCTION 1984
- DIAGNOSIS OF VENOUS THROMBOSIS AND PULMONARY-EMBOLISM 1982
- EXERCISE-INDUCED MYOCARDIAL ISCHEMIA EFFECTS ON ACTIVATION OF PLATELETS AND BLOOD-COAGULATION 1982
- THE ROLE OF ANTICOAGULANTS AND ANTI-PLATELET DRUGS IN CEREBROVASCULAR-DISEASE 1982
- Impact of Chemotherapy on Thrombin Generation and on the Protein C Pathway in Breast Cancer Patients. 37:88-97. 2010
- General Discussion. 34:31-34. 2005
- The Role of Ximelagatran in the Treatment of Venous Thromboembolism. 34:18-24. 2005
- Low-Molecular-Weight Heparin and Cancer Survival: Review of the Literature and Pooled Analysis of 1,726 Patients Treated for at Least Three Months. 33:197-201. 2003
- Risk Assessment and Primary VTE Prevention in the Cancer Patient. 33:36-41. 2003
- Management of thromboembolic disease in cancer patients.. 31 Suppl 1:68-69. 2001
- Conclusion. 29:128-129. 1999
- Low-Molecular-Weight Heparins in Acute Unstable Coronary Artery Disease – An Update. 29:72-75. 1999
- New Antithrombotic Drugs: Beyond Aspirin and Heparin. 29:68-68. 1999
- Optimization of Treatment for Venous Thromboembolism and Prevention of Recurrences. 29:79-80. 1999
- Thromboembolism: New Achievements and Challenges - Proceedings of the 6th International Symposium on Thromboembolic Diseases - Lisbon, June 4-5, 1999 - Preface. 29. 1999
- Antithrombotic Therapy in Coronary Ischaemia: The Expanding Role of Low-Molecular-Weight Heparin. 28:35-42. 1998
- Treatment of Venous Thromboembolism in Cancer Patients. 28:66-70. 1998
- Venous Thromboembolism in Malignancy and Malignancy in Venous Thromboembolism. 28:43-49. 1998
- Effect of Dermatan Sulphate on Activated Partial Thromboplastin Time Determined with Different Reagents. 27:85-90. 1997
- Low-Molecular-Weight Heparins and Unstable Angina – Current Perspectives. 27:19-24. 1997
- Treatment of Thrombotic Disorders in Cancer Patients. 27:38-43. 1997
- Management Of Venous Thromboembolism: Optimization By Clinical Trials. 26:220-226. 1996
- Diagnostic Problems with Venous Thromboembolic Disease in Pregnancy. 25:58-71. 1995
- The Diagnosis of Pulmonary Embolism. 25:72-87. 1995
- ORGARAN - EXTENDING THE FRONTIERS OF VENOUS THROMBOSIS PROPHYLAXIS - INTRODUCTION. 22:57-57. 1992
- ORGARAN - EXTENDING THE FRONTIERS OF VENOUS THROMBOSIS PROPHYLAXIS - SUMMARY AND CONCLUSIONS. 22:112-112. 1992
- Anticoagulant Mechanisms of Orgaran (Org 10172) and Its Fraction with High Affinity to Antithrombin III (Org 10849). 22:66-72. 1992
- Orgaran in the Prevention of Deep Vein Thrombosis in Stroke Patients. 22:92-98. 1992
- Warfarin-Induced Skin Necrosis in 2 Patients with Protein S Deficiency: Successful Reinstatement of Warfarin Therapy. 22:124-128. 1992
- Modulation of the Enzymatic Activity of α-Thrombin by Polyanions: Consequences on Intrinsic Activation of Factor V and Factor VIII. 21:240-247. 1991
- Thrombin Inhibition by Hirudin: How Hirudin Inhibits Thrombin. 21:27-31. 1991
- INVITRO AND EXVIVO ACTIVITIES OF CY216 - COMPARISON WITH OTHER LOW-MOLECULAR-WEIGHT HEPARINS. 20:180-192. 1990
- In vitro and ex vivo Activities of CY216: Comparison with Other Low Molecular Weight Heparins. 20:180-192. 1990
- Acute Effects with Reference to Thrombogenicity and Liver Toxicity after Injection of Different Coagulation Factor Concentrates. 19:152-159. 1989
- Heparin-induced Thrombocytopenia. 16:173-186. 1986
- INVIVO EFFECTS OF LOW-MOLECULAR-WEIGHT HEPARINS ON EXPERIMENTAL THROMBOSIS AND BLEEDING. 16:82-86. 1986
- In vivo Effects of Low Molecular Weight Heparins on Experimental Thrombosis and Bleeding. 16:82-86. 1986
- Platelet Interactions with the Endothelium and the Subendothelium: the Role of Thrombin and Prostacyclin. 8:183-192. 1979
- Preparation of human fibrinogen free of plasminogen by immunoadsorption. 1:210-214. 1973